Leo Pharma expands its arsenal of arguments for Adtralza with new long-term data
![Photo: Leo Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13241584.ece/ALTERNATES/schema-16_9/doc7hc0mg479c4w1hfriqm.jpg)
Leo Pharma has been developing the medicine tralokinumab for so long that it can now present data for the treament stretching over two years. The drug was already approved earlier this year as a treatment for atopic dermatitis in the EU under the name Adtralza.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.